ArticleJournal of nanobiotechnology2026
Self-assembling pH-responsive peptide nanoparticles delivering pyrvinium pamoate induce osteosarcoma senescence through CBX4 ubiquitination-mediated inhibition of YAP1 SUMOylation.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteosarcoma is a highly malignant and metastasis-prone bone tumor, and current treatment options remain unsatisfactory, underscoring the urgent need for new targeted strategies. Induction of cellular senescence represents a promising non-apoptotic antitumor mechanism. Although CK1α is considered to have tumor-suppressive potential, its underlying mechanism and the limited bioavailability of its specific activator pyrvinium pamoate (PP) have hindered clinical translation. Here, we developed a pH-responsive biomineralization-induced peptide self-assembly nanodelivery system (NP@PP) to improve the druggability of PP. Through in vitro and in vivo experiments combined with transcriptomic sequencing, co-immunoprecipitation, and Western blot analysis, we found that PP released from NP@PP efficiently activated CK1α and specifically promoted the ubiquitin-dependent degradation of CBX4. The loss of CBX4 further suppressed YAP1 SUMOylation and blocked its nuclear translocation, thereby activating p16
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.